Springer Science and Business Media LLC

Công bố khoa học tiêu biểu

* Dữ liệu chỉ mang tính chất tham khảo

Sắp xếp:  
Histone deacetylase inhibitors as a potential therapeutic agent for human cancer treatment
Springer Science and Business Media LLC - - 2006
Gregory Kouraklis, Evangelos P. Misiakos, Stamatios Theocharis
Annual Congress of the European Society for Medical Oncology (ESMO): Munich, Germany, 19–23 October 2018
Springer Science and Business Media LLC - Tập 13 - Trang 673-677 - 2018
Martin Chopra
The Unexpected Roles of Aurora A Kinase in Gliobastoma Recurrences
Springer Science and Business Media LLC - Tập 12 Số 1 - Trang 11-18 - 2017
Estelle Willems, Arnaud Lombard, Matthias Dedobbeleer, Nicolas Goffart, Bernard Rogister
Targeting Toll-Like Receptors for Cancer Therapy
Springer Science and Business Media LLC - Tập 13 - Trang 583-598 - 2018
Marc J. Braunstein, John Kucharczyk, Sylvia Adams
The immune system encompasses a broad array of defense mechanisms against foreign threats, including invading pathogens and transformed neoplastic cells. Toll-like receptors (TLRs) are critically involved in innate immunity, serving as pattern recognition receptors whose stimulation leads to additional innate and adaptive immune responses. Malignant cells exploit the natural immunomodulatory funct... hiện toàn bộ
Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients
Springer Science and Business Media LLC - Tập 12 - Trang 341-351 - 2017
Yuji Mishima, Satoshi Matsusaka, Keisho Chin, Mariko Mikuniya, Sayuri Minowa, Tomoko Takayama, Harumi Shibata, Ryoko Kuniyoshi, Mariko Ogura, Yasuhito Terui, Nobuyuki Mizunuma, Kiyohiko Hatake
A key to the successful use of targeted cancer therapy is the ability to preselect patients who are likely to benefit from the treatment according to molecular markers. Assessment for predicting therapy response is mostly done using tumor biopsies. However, these might not truly represent all of the patient’s malignant cells because of tumor heterogeneity and/or clonal evolution during disease pro... hiện toàn bộ
ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study
Springer Science and Business Media LLC - Tập 18 - Trang 571-583 - 2023
Michelle Wang, Shadera Slatter, Jesse Sussell, Chia-Wei Lin, Sarika Ogale, Debajyoti Datta, Atul J. Butte, Lyudmila Bazhenova, Vivek A. Rudrapatna
Randomized trials have demonstrated that anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) can be safe and efficacious treatments for patients with ALK-positive advanced non-small-cell lung cancer (aNSCLC). However, their safety, tolerability, effectiveness, and patterns of use in real-world patients remain understudied. We sought to assess the overall treatment pattern characteri... hiện toàn bộ
Simultaneously occurring chronic myelogenous leukemia and gastrointestinal stromal tumors treated with imatinib
Springer Science and Business Media LLC - - 2006
Yuji Mishima, Yasuhito Terui, Kengo Takeuchi, Eijiro Nagasaki, Masahiro Yokoyama, Nobuyuki Mizunuma, Shunji Takahashi, Katsushi Yamada, Tetsu Fukunaga, Junji Yamamoto, T. Yamaguchi, Yukio Kato, Kiyohiko Hatake
What’s Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma
Springer Science and Business Media LLC - Tập 17 - Trang 383-405 - 2022
Bruno Almeida Costa, Tarek H. Mouhieddine, Joshua Richter
Immunomodulatory drugs (IMiDs) have become an integral part of therapy for both newly diagnosed and relapsed/refractory multiple myeloma (RRMM). IMiDs bind to cereblon, leading to the degradation of proteins involved in B-cell survival and proliferation. Thalidomide, a first-generation IMiD, has little to no myelosuppressive potential, negligible renal clearance, and long-proven anti-myeloma activ... hiện toàn bộ
New agents in renal cell carcinoma
Springer Science and Business Media LLC - Tập 9 - Trang 183-193 - 2013
Raetasha Dabney, Ryan Devine, Nancy Sein, Benjamin George
Prior to 2005, the treatment options for metastatic renal cell carcinoma (mRCC) were limited. There has been a proliferation of agents since the introduction of sorafenib, sunitinib, and becavicumab for clinical use in advanced renal cell carcinoma. Recently, four new agents have been approved by the US Food and Drug Administration (FDA) for use in mRCC. These agents come from two unique targeted ... hiện toàn bộ
Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial
Springer Science and Business Media LLC - Tập 16 - Trang 47-57 - 2020
Céleste Lebbé, Antoine Italiano, Nadine Houédé, Ahmad Awada, Philippe Aftimos, Thierry Lesimple, Monica Dinulescu, Jan H. M. Schellens, Suzanne Leijen, Sylvie Rottey, Vibeke Kruse, Richard Kefford, Eric Raymond, Sandrine Faivre, Celine Pages, Carlos Gomez-Roca, Armin Schueler, Samantha Goodstal, Giorgio Massimini, Jean-Pierre Delord
Pimasertib is a selective, potent mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor. The aim of this study was to describe the efficacy, safety, and pharmacodynamics of pimasertib at pharmacologically active doses in a cohort of patients with locally advanced/metastatic melanoma from a first-in-human study of pimasertib. This was a phase I, open-label, two-part, dose-escalation study. Pa... hiện toàn bộ
Tổng số: 668   
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 10